The transaction is sourced from an 8-K filing with the SEC, filed via SEC EDGAR and published on April 29, 2024. The deal's current status is pending regulatory approval.
On the financial advisory side, Guggenheim Securities, LLC acted as exclusive financial advisor to Zoetis, the target/divesting party, in a lead capacity. Citi acted as exclusive financial advisor to Phibro, the acquirer, also in a lead capacity, per the respective source sentences pairing each financial advisor with its legal counsel.
On the legal side, Wachtell, Lipton, Rosen & Katz acted as legal advisor to Zoetis, the target, while Kirkland & Ellis LLP acted as legal advisor to Phibro, the acquirer.
Beyond the asset/product-line acquisition structure, with a disclosed deal value of $350,000,000, no further detail on which specific products within the MFA portfolio are included or excluded, or other structural terms, is provided in the facts block.
Several items are not disclosed in the available record. No further detail on the specific scope of the MFA product portfolio transferred is given beyond the general description, and no expected closing date or further timeline detail beyond the April 2024 filing date and pending-regulatory status is provided.